Labcorp reaffirms outlook through 2029 with 5%-8% revenue CAGR
Labcorp reaffirms full-year 2026 guidance and provided a long-term outlook through 2029. It expects compound annual revenue growth of 5% to 8% and compound annual adjusted EPS growth of 8.5% to 11.5%.
, Sept. m. ET, where the company will provide an in-depth review of its growth strategy, innovation roadmap and long-term financial outlook. The event will highlight Labcorp's unique position at the intersection of diagnostics, biopharma, science and technology and how the company is creating long-term value for customers and shareholders.